Matches in Ubergraph for { <http://purl.obolibrary.org/obo/NCIT_C15601> ?p ?o ?g. }
Showing items 1 to 44 of
44
with 100 items per page.
- NCIT_C15601 IAO_0000115 "A clinical research protocol designed to study a biomedical or behavioral intervention in a larger group of people (several hundred), to evaluate the drug's effectiveness for a particular indication in patients with the disease or condition under study, and to determine the common short-term side effects and risks associated with the intervention." @default.
- NCIT_C15601 NCIT_NHC0 "C15601" @default.
- NCIT_C15601 NCIT_P106 "Research Activity" @default.
- NCIT_C15601 NCIT_P108 "Phase II Trial" @default.
- NCIT_C15601 NCIT_P207 "C0282460" @default.
- NCIT_C15601 NCIT_P322 "CDISC" @default.
- NCIT_C15601 NCIT_P322 "CDISC-GLOSS" @default.
- NCIT_C15601 NCIT_P322 "PCDC" @default.
- NCIT_C15601 NCIT_P325 "A study to test whether a new treatment has an anticancer effect (for example, whether it shrinks a tumor or improves blood test results) and whether it works against a certain type of cancer." @default.
- NCIT_C15601 NCIT_P325 "Phase that includes the controlled clinical trials conducted to evaluate the safety and efficacy of the drug in a limited number of patients with the disease or condition under study. Objectives can be dose-ranging (dose-response, frequency of dosing), type of patients, or numerous other characteristics of safety and efficacy. [After 21 CRF Part 312.21 Phases of an investigation] See also phase, phase 2a, phase 2b. (CDISC Glossary)" @default.
- NCIT_C15601 NCIT_P325 "Phase that includes the controlled clinical trials conducted to evaluate the safety and efficacy of the drug in a limited number of patients with the disease or condition under study. Objectives can be dose-ranging (dose-response, frequency of dosing), type of patients, or numerous other characteristics of safety and efficacy. [After 21 CRF Part 312.21 Phases of an investigation] See also phase, phase 2a, phase 2b." @default.
- NCIT_C15601 NCIT_P366 "Phase_II_Trial" @default.
- NCIT_C15601 normalizedInformationContent "92.730304365937428" @default.
- NCIT_C15601 referenceCount "3" @default.
- NCIT_C15601 hasExactSynonym "2" @default.
- NCIT_C15601 hasExactSynonym "Clinical Trials, Phase II" @default.
- NCIT_C15601 hasExactSynonym "PHASE II TRIAL" @default.
- NCIT_C15601 hasExactSynonym "Phase 2 Study" @default.
- NCIT_C15601 hasExactSynonym "Phase 2" @default.
- NCIT_C15601 hasExactSynonym "Phase II Clinical Trial" @default.
- NCIT_C15601 hasExactSynonym "Phase II Protocol" @default.
- NCIT_C15601 hasExactSynonym "Phase II Study" @default.
- NCIT_C15601 hasExactSynonym "Phase II Trial" @default.
- NCIT_C15601 hasExactSynonym "Trial Phase 2" @default.
- NCIT_C15601 hasExactSynonym "phase 2" @default.
- NCIT_C15601 hasExactSynonym "phase II trial" @default.
- NCIT_C15601 inSubset NCIT_C132298 @default.
- NCIT_C15601 inSubset NCIT_C186309 @default.
- NCIT_C15601 inSubset NCIT_C186341 @default.
- NCIT_C15601 inSubset NCIT_C188693 @default.
- NCIT_C15601 inSubset NCIT_C61410 @default.
- NCIT_C15601 inSubset NCIT_C66737 @default.
- NCIT_C15601 inSubset NCIT_C66830 @default.
- NCIT_C15601 inSubset NCIT_C67497 @default.
- NCIT_C15601 type Class @default.
- NCIT_C15601 isDefinedBy ncit.owl @default.
- NCIT_C15601 label "Phase II Trial" @default.
- NCIT_C15601 subClassOf NCIT_C15206 @default.
- NCIT_C15601 subClassOf NCIT_C15429 @default.
- NCIT_C15601 subClassOf NCIT_C15601 @default.
- NCIT_C15601 subClassOf NCIT_C16203 @default.
- NCIT_C15601 subClassOf NCIT_C43431 @default.
- NCIT_C15601 subClassOf NCIT_C63536 @default.
- NCIT_C15601 subClassOf NCIT_C70820 @default.